{"id":"atgc-100-100u","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATGC-100 appears to be a recombinant or modified antithrombin product designed to potentiate endogenous anticoagulation mechanisms. Antithrombin is a natural inhibitor of thrombin and other coagulation factors, and this formulation may be engineered for improved stability, bioavailability, or therapeutic efficacy in thrombotic conditions.","oneSentence":"ATGC-100 is an antithrombin-based therapeutic that enhances natural anticoagulation pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:57.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombotic disorders or thromboembolism prevention (specific indication in Phase 3 not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT04830345","phase":"PHASE3","title":"Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-06-29","conditions":"Glabellar Frown Lines","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":179,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ATGC-100 100U","genericName":"ATGC-100 100U","companyName":"EuBiologics Co.,Ltd","companyId":"eubiologics-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ATGC-100 100U is a small molecule being studied in a Phase 3 clinical trial for the treatment of moderate to severe glabellar frown lines. The trial is comparing the efficacy and safety of ATGC-100 100U to Botox 100U.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}